David Hägg

Publikationer
Populärvetenskap och samverkan

Artiklar

Article: BRITISH JOURNAL OF DERMATOLOGY. 2026;194(3):481-488
The risk of venous thromboembolism in atopic dermatitis: a population-based cohort study
Ivert LU; Anveden-Berglind I; Gembert K; Eriksson J; Hernan Giunta D; Hagg D; Linder M
Article: CLINICAL EPIDEMIOLOGY. 2025;17:747-752
Positive Predictive Value of ICD-10 Codes for Identifying Hypocalcemia in Women with Postmenopausal Osteoporosis in Swedish Patient Register: A Validation Study
Kjellman A; Kim M; Lundgren P-O; Thiel T; Thor A; Thulin H; Hagg D; Ehrenstein V
Article: GENERAL HOSPITAL PSYCHIATRY. 2024;89:23-31
Association between inflammatory joint disease and severe or treatment-resistant depression: population-based cohort and case-control studies in Sweden
Brenner P; Askling J; Hagg D; Brandt L; Stang P; Reutfors J
Journal article: EUROPEAN PSYCHIATRY. 2024;67:s534
The risk for inflammatory joint disease in patients with severe or treatment-resistant depression: populationbased cohort study in Sweden
Brenner P; Askling J; Hagg D; Brandt L; Stang P; Reutfors J
Article: BMC MEDICINE. 2024;22(1):84
Estrogen-modulating treatment among mid-life women and COVID-19 morbidity and mortality: a multiregister nationwide matched cohort study in Sweden
Elenis E; Kallner HK; Karalexi MA; Haegg D; Linder M; Fall K; Papadopoulos FC; Skalkidou A
Article: BMJ OPEN. 2023;13(2):e066057
Methodology of the brodalumab assessment of hazards: a multicentre observational safety (BRAHMS) study
Reilev M; Jensen PB; Ranch LS; Egeberg A; Furu K; Gembert K; Hagg D; Haug U; Karlstad O; Reutfors J; Schaefer W; Schwartz S; Smits E; Holthius E; Herings R; Trifiro G; Kirchmayer U; Rosa AC; Belleudi V; Gini R; Stovring H; Hallas J
Article: NEUROLOGY AND THERAPY. 2022;11(4):1659-1676
Risk of Major Cardiovascular and Cerebrovascular Events in Users of Lisdexamfetamine and Other Medications for Attention-Deficit/Hyperactivity Disorder in Denmark and Sweden: A Population-Based Cohort Study
Forns J; Dudukina E; Hagg D; Szentkuti P; Gembert K; Plana E; Gilsenan A; Horvath-Puho E; Ehrenstein V; Reutfors J; Rebordosa C
Article: INTERNATIONAL JOURNAL OF PSYCHIATRY IN CLINICAL PRACTICE. 2022;26(3):251-258
Health care utilisation in treatment-resistant depression: a Swedish population-based cohort study
Brenner P; Nygren A; Hagg D; Tiger M; O'Hara M; Brandt L; Reutfors J
Article: JAAD INTERNATIONAL. 2021;3:63-75
Societal impact for patients with psoriasis: A nationwide Swedish register study
Habel H; Wettermark B; Hagg D; Villacorta R; Wennerstrom ECM; Linder M
Article: PLOS ONE. 2020;15(7):e0236434
A register-based approach to identifying treatment-resistant depression-Comparison with clinical definitions
Hagg D; Brenner P; Reutfors J; Li G; DiBernardo A; Boden R; Brandt L
Article: CLINICAL EPIDEMIOLOGY. 2020;12:737-744
The Occurrence of Metabolic Risk Factors Stratified by Psoriasis Severity: A Swedish Population-Based Matched Cohort Study
Hajiebrahimi M; Song C; Hagg D; Andersson TM-L; Villacorta R; Linder M
Article: JOURNAL OF AFFECTIVE DISORDERS. 2019;249:242-252
Antidepressant use in Denmark, Germany, Spain, and Sweden between 2009 and 2014: Incidence and comorbidities of antidepressant initiators
Forns J; Pottegard A; Reinders T; Poblador-Plou B; Morros R; Brandt L; Cainzos-Achirica M; Hellfritzsch M; Schink T; Prados-Torres A; Giner-Soriano M; Hagg D; Hallas J; Cortes J; Jacquot E; Detour N; Perez-Gutthann S; Pladevall M; Reutfors J
Article: CNS DRUGS. 2019;33(4):383-395
Risk of Acute Liver Injury in Agomelatine and Other Antidepressant Users in Four European Countries: A Cohort and Nested Case-Control Study Using Automated Health Data Sources
Pladevall-Vila M; Pottegard A; Schink T; Reutfors J; Morros R; Poblador-Plou B; Timmer A; Forns J; Hellfritzsch M; Reinders T; Hagg D; Giner-Soriano M; Prados-Torres A; Cainzos-Achirica M; Hallas J; Brandt L; Cortes J; Aguado J; Perlemuter G; Falissard B; Castellsague J; Jacquot E; Deltour N; Perez-Gutthann S
Article: JOURNAL OF AFFECTIVE DISORDERS. 2018;238:674-679
Mortality in treatment-resistant unipolar depression: A register-based cohort study in Sweden
Reutfors J; Andersson TM-L; Brenner P; Brandt L; DiBernardo A; Li G; Hagg D; Wingard L; Boden R
Article: CLINICAL EPIDEMIOLOGY. 2018;10:705-715
Young patients with risk factors prevalent in the elderly - differences in comorbidity depending on severity of psoriasis: a nationwide cross-sectional study in Swedish health registers
Hajiebrahimi M; Linder M; Hagg D; Berglind IA; McElligott S; Valgardsson VS; Villacorta R; Sundstrom A
Article: AMERICAN JOURNAL OF CLINICAL DERMATOLOGY. 2017;18(4):583-590
Severity of Psoriasis Differs Between Men and Women: A Study of the Clinical Outcome Measure Psoriasis Area and Severity Index (PASI) in 5438 Swedish Register Patients
Hagg D; Sundstrom A; Eriksson M; Schmitt-Egenolf M
Article: BMC MEDICAL GENETICS. 2015;16:79
Hair shaft structures in EDAR induced ectodermal dysplasia
Stecksen-Blicks C; Kieri CF; Hagg D; Schmitt-Egenolf M
Article: JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY. 2015;29(3):452-456
Decision for biological treatment in real life is more strongly associated with the Psoriasis Area and Severity Index (PASI) than with the Dermatology Life Quality Index (DLQI)
Hagg D; Sundstrom A; Eriksson M; Schmitt-Egenolf M
Article: PLOS ONE. 2013;8(5):e63619
The Higher Proportion of Men with Psoriasis Treated with Biologics May Be Explained by More Severe Disease in Men
Hagg D; Eriksson M; Sundstrom A; Schmitt-Egenolf M

Alla övriga publikationer

Conference publication: ACTA DERMATO-VENEREOLOGICA. 2025;105
THE RISK OF VENOUS THROMBOEMBOLISM IN ATOPIC DERMATITIS: A POPULATION-BASED COHORT STUDY
Ivert LU; Anveden-Berglind I; Gembert K; Eriksson J; Giunta DH; Hagg D; Linder M
Conference publication: PHARMACOEPIDEMIOLOGY AND DRUG SAFETY. 2022;31:487-488
Brodalumab assessment of hazards: A multinational safety (brahms) study of a biological anti-psoriatic drug across six European countries
Reilev M; Jensen P; Stovring H; Ranch LS; Gini R; Bartolini CC; Trifiro G; Kirchmayer U; Rosa AC; Belleudi V; Haug U; Schwarz S; Schaefer W; Herings R; Smits E; Overbeek J; Holthuis E; Furu K; Gembert K; Hagg D; Tari M; Ientile V; Ingrasciotta Y; Egeberg A; Hallas J
Conference publication: EUROPEAN PSYCHIATRY. 2022;65:S111
Association with severe and treatment-resistant depression among patients with inflammatory joint disease. Nationwide nested case-control study in Swedish registers.
Brenner P; Askling J; Stang P; Brandt L; Hagg D; Reutfors J
Conference publication: EUROPEAN NEUROPSYCHOPHARMACOLOGY. 2021;53:S77
Health care utilization in treatment-resistant depression: a Swedish population based cohort study
Brenner P; Nygren A; Hagg D; Tiger M; O'Hara M; Brandt L; Reutfors J
Conference publication: PHARMACOEPIDEMIOLOGY AND DRUG SAFETY. 2020;29:84-85
Occurrence of metabolic risk factors stratified by psoriasis severity: A Swedish population-based matched cohort study
Hagg D; Linder M; Hajiebrahimi M; Song C; Andersson TM-L; Villacorta R
Conference publication: PHARMACOEPIDEMIOLOGY AND DRUG SAFETY. 2019;28:274-275
Antidepressant use in Denmark, Germany, Spain, and Sweden from 2009 to 2014: Incidence and comorbidities of antidepressant initiators
Forns J; Pottegard A; Reinders T; Poblador-Plou B; Morros R; Brandt L; Cainzos-Achirica M; Hellfritzsch M; Schink T; Prados-Torres A; Giner-Soriano M; Hagg D; Hallas J; Cortes J; Jacquot E; Deltour N; Perez-Gutthann S; Pladevall M; Reutfors J
Conference publication: PHARMACOEPIDEMIOLOGY AND DRUG SAFETY. 2019;28:104-105
Eye color and risk of ocular melanoma in patients with glaucoma - a Swedish register study combining data from the Swedish police Authority's register on passport applications and National Health Registers
Hagg D; Berglind IA; Kieler H; Linder M; Odsbu I
Conference publication: EUROPEAN NEUROPSYCHOPHARMACOLOGY. 2019;29:S589-S590
Agomelatine and other antidepressants and the risk of acute liver injury (ALI), a post authorisation safety study (PASS) in four European countries
Pladelvall M; Pottegard A; Schink T; Reutfors J; Morros R; Poblador-Plou B; Timmer A; Forns J; Hellfritzsch M; Reinders T; Hagg D; Giner-Soriano M; Prados-Torres A; Cainzos-Achirica M; Hallas J; Kollhorst B; Brandt L; Cortes J; Aguado J; Perlemuter G; Falissard B; Castellsague J; Jacquot E; Deltour N; Perez-Gutthann S
Conference publication: PHARMACOEPIDEMIOLOGY AND DRUG SAFETY. 2018;27:152
Treatment resistant depression as a risk factor for substance use disorders-A national register-based cohort study
Brenner P; Hagg D; DiBernardo A; Li G; Boden R; Brandt L; Reutfors J
Conference publication: PHARMACOEPIDEMIOLOGY AND DRUG SAFETY. 2018;27:19-20
Agomelatine and other antidepressants and the risk of acute liver injury (ALI), a pass in four European countries
Pladevall M; Hallas J; Schink T; Reutfors J; Morros R; Poblador-Plou B; Forns J; Hellfritzsch M; Reinders T; Hagg D; Giner-Soriano M; Prados-Torres A; Cainzos-Achirica M; Pottegard A; Kollhorst B; Brandt L; Cortes J; Aguado J; Perlemuter G; Castellsague J; Jacquot E; Deltour N; Perez-Gutthann S
Conference publication: PHARMACOEPIDEMIOLOGY AND DRUG SAFETY. 2018;27:153
Substance use disorders are risk factors for treatment resistant depression
Brenner P; Brandt L; Hagg D; Li G; DiBernardo A; Boden R; Reutfors J
Conference publication: PHARMACOEPIDEMIOLOGY AND DRUG SAFETY. 2017;26:379-380
Demographics and Prevalence of Comorbidities for Patients with Mild, Moderate, and Severe Psoriasis
Hajiebrahimi M; Sundstrom A; Hagg D; McElligott S; Valgardsson S; Villacorta R; Linder M
Conference publication: PHARMACOEPIDEMIOLOGY AND DRUG SAFETY. 2017;26:266-267
A Population-Based Cohort Study to Assess the Potential Association Between Latanoprost Use and Primary Ocular Melanoma and Facial Cutaneous Melanoma
George P; Kieler H; Berglind I; Linder M; Hagg D; Xu W; Li Q; Zhou D; Schachar RA
Conference publication: PHARMACOEPIDEMIOLOGY AND DRUG SAFETY. 2017;26:581
Utilization Patterns of Denosumab and Bisphosphonates in Denmark, Norway and Sweden Between 2010 and 2015: A Descriptive Study Among Women Aged 50 Years and Above
Westerlund A; Hagg D; Lunde A; Tell GS; Kahlert J; Ehrenstein V; Kieler H; Sundstrom A
Conference publication: PHARMACOEPIDEMIOLOGY AND DRUG SAFETY. 2016;25:4-5
Psoriasis Patients New to Specialist Care in Sweden 2007-2009: A Two-Year Follow-Up of Treatment Allocation
Hagg D; Eriksson M; Schmitt-Egenolf M; Sundstrom A
Conference publication: PHARMACOEPIDEMIOLOGY AND DRUG SAFETY. 2016;25:540
Fracture-Preventing Benefit of Bisphosphonates by Compliance and Its Timing Following Therapy Start: A Register-Based Study of Postmenopausal Women in Sweden
Westerlund A; Hagg D; Svensson T; Granath F; Kieler H

Artiklar

Alla övriga publikationer

Nyheter från KI

Kalenderhändelser från KI